71 West Capital Partners Makes New $695,000 Investment in Axon Enterprise, Inc $AXON

71 West Capital Partners acquired a new position in Axon Enterprise, Inc (NASDAQ:AXON) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,224 shares of the biotechnology company’s stock, valued at approximately $695,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Evergreen Capital Management LLC grew its stake in shares of Axon Enterprise by 3.8% in the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after buying an additional 15 shares in the last quarter. Wealth Alliance LLC grew its stake in shares of Axon Enterprise by 3.2% in the 3rd quarter. Wealth Alliance LLC now owns 583 shares of the biotechnology company’s stock worth $419,000 after buying an additional 18 shares in the last quarter. Quadrant Capital Group LLC grew its stake in shares of Axon Enterprise by 0.5% in the 3rd quarter. Quadrant Capital Group LLC now owns 3,968 shares of the biotechnology company’s stock worth $2,848,000 after buying an additional 19 shares in the last quarter. CWA Asset Management Group LLC grew its stake in shares of Axon Enterprise by 5.2% in the 4th quarter. CWA Asset Management Group LLC now owns 387 shares of the biotechnology company’s stock worth $220,000 after buying an additional 19 shares in the last quarter. Finally, Synergy Financial Group LTD grew its stake in shares of Axon Enterprise by 1.4% in the 3rd quarter. Synergy Financial Group LTD now owns 1,388 shares of the biotechnology company’s stock worth $996,000 after buying an additional 19 shares in the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Axon Enterprise

In related news, President Joshua Isner sold 13,000 shares of Axon Enterprise stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $488.45, for a total transaction of $6,349,850.00. Following the completion of the sale, the president owned 169,125 shares in the company, valued at $82,609,106.25. This trade represents a 7.14% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Caitlin Elizabeth Kalinowski sold 564 shares of Axon Enterprise stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $478.97, for a total transaction of $270,139.08. Following the sale, the director owned 3,632 shares of the company’s stock, valued at $1,739,619.04. The trade was a 13.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 38,989 shares of company stock worth $19,090,083 over the last ninety days. 4.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on AXON. Royal Bank Of Canada dropped their price target on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a research note on Wednesday, February 25th. Needham & Company LLC dropped their price target on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Craig Hallum reaffirmed a “buy” rating and set a $820.00 price target on shares of Axon Enterprise in a research note on Wednesday, February 25th. Citizens Jmp dropped their price target on shares of Axon Enterprise from $825.00 to $700.00 and set a “market outperform” rating for the company in a research note on Thursday, May 7th. Finally, UBS Group dropped their price target on shares of Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating for the company in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $712.75.

Axon Enterprise Price Performance

AXON stock opened at $443.21 on Tuesday. Axon Enterprise, Inc has a 12 month low of $339.01 and a 12 month high of $885.91. The company has a current ratio of 2.27, a quick ratio of 1.93 and a debt-to-equity ratio of 0.49. The company has a 50-day moving average price of $410.95 and a 200 day moving average price of $488.34. The stock has a market cap of $35.72 billion, a PE ratio of 178.00, a P/E/G ratio of 8.03 and a beta of 1.45.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The firm had revenue of $807.35 million during the quarter, compared to analysts’ expectations of $778.91 million. During the same period in the previous year, the company earned $1.47 EPS. The firm’s revenue for the quarter was up 33.7% compared to the same quarter last year. Equities research analysts anticipate that Axon Enterprise, Inc will post 1.82 earnings per share for the current year.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.